BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 20, 2026
Home » Authors » Tamra Sami

Articles by Tamra Sami

Australia seeks industry feedback on aligning device definitions more closely with the EU

Jan. 14, 2019
By Tamra Sami

Australia proposes unique device identification system

Jan. 11, 2019
By Tamra Sami

Qiagen licenses Ellume's TB digital diagnostic, invests $15M

Jan. 10, 2019
By Tamra Sami

Australian researchers harness AI to sequence human genome, diagnose PTSD, breast cancer

Jan. 2, 2019
By Tamra Sami
BRISBANE, Australia – Australian researchers are using artificial intelligence (AI) to diagnose medical conditions ranging from breast cancer to post-traumatic stress disorder (PTSD) more quickly than ever before.
Read More

Australian researchers harness AI to sequence human genome, diagnose PTSD, breast cancer

Dec. 28, 2018
By Tamra Sami
BRISBANE, Australia – Australian researchers are using artificial intelligence (AI) to diagnose medical conditions ranging from breast cancer to post-traumatic stress disorder (PTSD) more quickly than ever before.
Read More

Starpharma out-licenses Vivagel BV to ITF Pharma for U.S. market for $101M

Dec. 26, 2018
By Tamra Sami
PERTH, Australia – In yet another regional carve-out deal for Starpharma Holdings Ltd., the company has out-licensed rights to its Vivagel BV for bacterial vaginosis (BV) to ITF Pharma for the U.S. market for roughly $101 million.
Read More

Investment in Australian life sciences on the rise but at a conservative clip

Dec. 26, 2018
By Tamra Sami
PERTH, Australia – More money will be deployed in Australia's life sciences sector in the next four or five years than there has ever been, according to Australia's biggest life sciences investor. Brandon Capital Partners manages four life sciences funds with A$531 million (US$374.1 million) under management. Although it's the biggest venture fund in Australia, it's fairly small compared to some of its U.S. peers.
Read More

Investment in Australian life sciences on the rise but at a conservative clip

Dec. 24, 2018
By Tamra Sami

Investment in Australian life sciences on the rise but at a conservative clip

Dec. 24, 2018
By Tamra Sami
PERTH, Australia – More money will be deployed in Australia's life sciences sector in the next four or five years than there has ever been, according to Australia's biggest life sciences investor.
Read More

Australia's TGA unveils guidance on software as a medical device

Dec. 21, 2018
By Tamra Sami
Previous 1 2 … 200 201 202 203 204 205 206 207 208 … 235 236 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Wireframe of feet and scale

    GLP-1s need technologies for long-term use

    BioWorld
    For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
  • UTRN gene involved in arthrogryposis, study finds

    BioWorld Science
    Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
  • Blue-gray dollar sign

    HMNC raises $50M series B to prep depression drugs for phase III

    BioWorld
    HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing